Niels W. Boone
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Niels W. Boone has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Paul-Hugo Marie van der Kuy
Department of Hospital Pharmacy, Erasmus Medical Center, Rotterdam, Netherlands
3 shared publications Ralph Peeters
Department of Rheumatology Zuyderland Medical Centre Heerlen The Netherlands
3 shared publicationsA. A. van Bodegraven
Department of Gastroenterology, Geriatrics, Internal and Intensive Care Medicine (Co-MIK), Zuyderland Medical Centre, Sittard-Geleen / Heerlen, The Netherlands
2 shared publications- Alexandre Sepriano
NOVA Medical School, Universidade NOVA de Lisboa, Lisbon, Portugal; Department of Rheumatology, Hospital de Egas Moniz-ULSLO, Lisbon, Portugal
2 shared publications Dennis R. Wong
Department of Clinical Pharmacy, Pharmacology and Toxicology, Zuyderland Medical Centre Heerlen The Netherlands
2 shared publicationsRob Janknegt
Department of Clinical Pharmacy, Pharmacology and Toxicology, Zuyderland Medical Centre Sittard-Geleen, Sittard-Geleen, Limburg, The Netherlands
2 shared publications
Latest Publications
- 18 September 2026
- Published by Wiley in British Journal of Clinical Pharmacology
Switching standard dosed intravenous to subcutaneous infliximab leads to similar drug exposure in inflammatory bowel disease patients independent of concomitant immunosuppressants (SHUFFLE study)
Aims: Subcutaneous (SC) flat‐dose infliximab (IFX) biosimilar offers potential advantages over intravenous (IV) weight‐based dosing. Prospective pharmacokinetic data and clinical outcomes in inflammatory bowel disease (IBD) are scarce, since drug approval was primarily based on a rheumatoid‐arthritis study population concomitantly using methotrexate. We aim to compare IFX exposure during IV and SC therapy in IBD patients and address the effect of concomitant immunosuppressants. Methods: In this single‐centre, prospective study, adult IBD patients in clinical remission on a 6–8 weekly IFX IV‐dosing interval were switched to biweekly SC IFX and followed for 24 weeks. Primary endpoint was the area under the concentration‐time curves (AUCs). Secondary endpoints included trough levels, time burden and quality‐of‐life (inflammatory bowel disease questionnaire [IBDQ‐NL]). As an additional follow‐up assessment, trough levels at ≥12 months were compared across IFX mono‐, combination‐ and immunosuppressant discontinuation groups. Results: Thirty‐five patients were evaluated: 20 received IFX monotherapy and 15 IFX combination therapy. Mean AUCs 6–8 weeks were comparable between IV and SC administration, independent of immune suppressive. IFX trough levels increased on SC IFX median 4.6 mg/L vs .16.1 mg/L ( p < 0.05), independent of concomitant immunosuppressants. These results were consistent at ≥12 months, regardless of monotherapy, combination therapy or immunosuppressant discontinuation. Time burden decreased substantially (median −9.3 h/6 months, p < 0.05), and IBDQ‐NL score increased (189–197, p < 0.05). There were no exacerbations during follow‐up. After 24 weeks, 97% were still being treated with IFX SC. Conclusions: SC IFX in IBD patients maintained equivalent drug exposure with higher trough levels, reduced time burden and stable quality‐of‐life, independent of concomitant immunosuppressants.
- 18 September 2026
- Published by Wiley in British Journal of Clinical Pharmacology
Switching standard dosed intravenous to subcutaneous infliximab leads to similar drug exposure in inflammatory bowel disease patients independent of concomitant immunosuppressants (SHUFFLE study)
Aims: Subcutaneous (SC) flat‐dose infliximab (IFX) biosimilar offers potential advantages over intravenous (IV) weight‐based dosing. Prospective pharmacokinetic data and clinical outcomes in inflammatory bowel disease (IBD) are scarce, since drug approval was primarily based on a rheumatoid‐arthritis study population concomitantly using methotrexate. We aim to compare IFX exposure during IV and SC therapy in IBD patients and address the effect of concomitant immunosuppressants. Methods: In this single‐centre, prospective study, adult IBD patients in clinical remission on a 6–8 weekly IFX IV‐dosing interval were switched to biweekly SC IFX and followed for 24 weeks. Primary endpoint was the area under the concentration‐time curves (AUCs). Secondary endpoints included trough levels, time burden and quality‐of‐life (inflammatory bowel disease questionnaire [IBDQ‐NL]). As an additional follow‐up assessment, trough levels at ≥12 months were compared across IFX mono‐, combination‐ and immunosuppressant discontinuation groups. Results: Thirty‐five patients were evaluated: 20 received IFX monotherapy and 15 IFX combination therapy. Mean AUCs 6–8 weeks were comparable between IV and SC administration, independent of immune suppressive. IFX trough levels increased on SC IFX median 4.6 mg/L vs .16.1 mg/L ( p < 0.05), independent of concomitant immunosuppressants. These results were consistent at ≥12 months, regardless of monotherapy, combination therapy or immunosuppressant discontinuation. Time burden decreased substantially (median −9.3 h/6 months, p < 0.05), and IBDQ‐NL score increased (189–197, p < 0.05). There were no exacerbations during follow‐up. After 24 weeks, 97% were still being treated with IFX SC. Conclusions: SC IFX in IBD patients maintained equivalent drug exposure with higher trough levels, reduced time burden and stable quality‐of‐life, independent of concomitant immunosuppressants.
- 13 November 2025
- Published by Springer Nature in Clinical Rheumatology
- Vol. 45 (1) , 73-79
Cost optimizing tocilizumab therapy in stable rheumatoid arthritis: a dose de-escalation nomogram to prevent overuse and unnecessary costs
Background The conventional 8 mg/kg tocilizumab (TCZ) dose regimen for rheumatoid arthritis (RA) yields higher serum trough concentrations (TCZtrough) than needed (> 1 mg/L) for C-reactive protein normalization and disease control. We evaluated the registered dosing approach by TCZtrough assessment using pharmacokinetic (PK) modelling and introduced a practical TCZtrough-guided dose reduction nomogram. Methods This prospective cohort study examined RA patients with stable disease activity undergoing intravenous TCZ treatment. A population PK model was constructed utilizing literature PK-data, TCZtrough, and dosing information. The derived model enabled prediction of TCZtrough guided dose de-escalation constructed in a nomogram. Dose reduction was implemented in a study subgroup, involving a reassessment of TCZtrough and maintenance of disease activity control. Results In 39 patients treated according to the registered dose-scheme, the baseline mean TCZtrough was 27.6 mg/L (SD 12.6). Simulations using the constructed PK-model demonstrated that a 0.4–4.6 mg/kg dose reduction was feasible in 36 patients (92%). The simulated reduction corresponds with an annual cost-reduction of approximately 25% per patient. Twelve consecutive patients were selected for the prospective validation of a model-based dose reduction nomogram. In all patients TCZtrough remained above 1 mg/L upon reduction, while the median TCZtrough decreased by 25 mg/L. After 18 months, 75% (n = 9) of these patients continued to receive reduced TCZ dosages, while maintaining stable disease. Conclusions TCZtrough guided dose de-escalation based on a proposed nomogram results in considerable cost reductions, while efficacy is maintained in most patients. Through routine monitoring of TCZtrough in stable RA patients, dose reduction can be implemented, potentially leading to optimization of cost-effective TCZ therapy. Key Points • Tocilizumab (TCZ) levels at a registered dosage (8 mg/kg) substantially exceed the minimally required concentration for disease control. • Although the pharmacokinetics of TCZ are well established, TCZ trough levels (TCZtrough) are rarely used to guide individualized dose reduction strategies in routine RA practice. • When reducing TCZ use, dose reduction is preferred above extending the dose interval for achieving sufficient TCZtrough. • Dose de-escalation based on TCZtrough measurement and a nomogram leads to a substantial dose reduction while maintaining efficacy, potentially reducing TCZ costs by 25%.
- 13 November 2025
- Published by Springer Nature in Clinical Rheumatology
- Vol. 45 (1) , 73-79
Cost optimizing tocilizumab therapy in stable rheumatoid arthritis: a dose de-escalation nomogram to prevent overuse and unnecessary costs
Background The conventional 8 mg/kg tocilizumab (TCZ) dose regimen for rheumatoid arthritis (RA) yields higher serum trough concentrations (TCZtrough) than needed (> 1 mg/L) for C-reactive protein normalization and disease control. We evaluated the registered dosing approach by TCZtrough assessment using pharmacokinetic (PK) modelling and introduced a practical TCZtrough-guided dose reduction nomogram. Methods This prospective cohort study examined RA patients with stable disease activity undergoing intravenous TCZ treatment. A population PK model was constructed utilizing literature PK-data, TCZtrough, and dosing information. The derived model enabled prediction of TCZtrough guided dose de-escalation constructed in a nomogram. Dose reduction was implemented in a study subgroup, involving a reassessment of TCZtrough and maintenance of disease activity control. Results In 39 patients treated according to the registered dose-scheme, the baseline mean TCZtrough was 27.6 mg/L (SD 12.6). Simulations using the constructed PK-model demonstrated that a 0.4–4.6 mg/kg dose reduction was feasible in 36 patients (92%). The simulated reduction corresponds with an annual cost-reduction of approximately 25% per patient. Twelve consecutive patients were selected for the prospective validation of a model-based dose reduction nomogram. In all patients TCZtrough remained above 1 mg/L upon reduction, while the median TCZtrough decreased by 25 mg/L. After 18 months, 75% (n = 9) of these patients continued to receive reduced TCZ dosages, while maintaining stable disease. Conclusions TCZtrough guided dose de-escalation based on a proposed nomogram results in considerable cost reductions, while efficacy is maintained in most patients. Through routine monitoring of TCZtrough in stable RA patients, dose reduction can be implemented, potentially leading to optimization of cost-effective TCZ therapy. Key Points • Tocilizumab (TCZ) levels at a registered dosage (8 mg/kg) substantially exceed the minimally required concentration for disease control. • Although the pharmacokinetics of TCZ are well established, TCZ trough levels (TCZtrough) are rarely used to guide individualized dose reduction strategies in routine RA practice. • When reducing TCZ use, dose reduction is preferred above extending the dose interval for achieving sufficient TCZtrough. • Dose de-escalation based on TCZtrough measurement and a nomogram leads to a substantial dose reduction while maintaining efficacy, potentially reducing TCZ costs by 25%.
- 24 February 2023
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 91 (4) , 938-946
Single dose tocilizumab for COVID‐19 associated cytokine storm syndrome: Less is more
Aims: We aim to evaluate the clinical pharmacokinetics of a single dose interleukin‐6 (IL‐6) antibody tocilizumab (TCZ) in methylprednisolone (MP)‐treated COVID‐19 patients with cytokine storm syndrome (CSS).Methods: MP pre‐treated patients with COVID‐19‐associated CSS, defined as at least two elevations of C‐reactive protein (CRP) >100 mg/L, ferritin >900 μg/L or D‐dimers >1500 μg/L, received intravenous TCZ (8 mg/kg, max. 800 mg) upon clinical deterioration. A nonlinear‐mixed effects model was developed based on TCZ serum concentrations and dosing information. Population pharmacokinetic parameters were estimated and concentration–time profiles were plotted against individual predicted values. Fixed dose simulations were subsequently performed based on the final model.Results: In total 40 patients (mean [SD] age: 62 [12] years, 20% female, body weight: 87 [17] kg) with COVID‐19 induced CSS were evaluated on pharmacokinetics and laboratory parameters. A biphasic elimination of TCZ serum concentration was described by a homogeneous population pharmacokinetic model. Serum TCZ concentrations above the 1 μg/L target saturation threshold were covered for 16 days in all evaluated patients treated with a single dose of 8 mg/kg. In a simulation with TCZ 400 mg fixed dose, this condition of full IL‐6 receptor occupancy at minimum serum concentration was also met.Conclusions: A single dose (8 mg/kg, max. 800 mg) is sufficient to cover a period of 16 days of IL‐6‐mediated hyperinflammation in COVID‐19‐induced CSS in MP‐treated patients. Based on body weight PK simulations, a fixed‐dose tocilizumab of 400 mg should be considered to prevent overtreatment, future drug shortage and unnecessary drug expenditure.
- 24 February 2023
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 91 (4) , 938-946
Single dose tocilizumab for COVID‐19 associated cytokine storm syndrome: Less is more
Aims: We aim to evaluate the clinical pharmacokinetics of a single dose interleukin‐6 (IL‐6) antibody tocilizumab (TCZ) in methylprednisolone (MP)‐treated COVID‐19 patients with cytokine storm syndrome (CSS).Methods: MP pre‐treated patients with COVID‐19‐associated CSS, defined as at least two elevations of C‐reactive protein (CRP) >100 mg/L, ferritin >900 μg/L or D‐dimers >1500 μg/L, received intravenous TCZ (8 mg/kg, max. 800 mg) upon clinical deterioration. A nonlinear‐mixed effects model was developed based on TCZ serum concentrations and dosing information. Population pharmacokinetic parameters were estimated and concentration–time profiles were plotted against individual predicted values. Fixed dose simulations were subsequently performed based on the final model.Results: In total 40 patients (mean [SD] age: 62 [12] years, 20% female, body weight: 87 [17] kg) with COVID‐19 induced CSS were evaluated on pharmacokinetics and laboratory parameters. A biphasic elimination of TCZ serum concentration was described by a homogeneous population pharmacokinetic model. Serum TCZ concentrations above the 1 μg/L target saturation threshold were covered for 16 days in all evaluated patients treated with a single dose of 8 mg/kg. In a simulation with TCZ 400 mg fixed dose, this condition of full IL‐6 receptor occupancy at minimum serum concentration was also met.Conclusions: A single dose (8 mg/kg, max. 800 mg) is sufficient to cover a period of 16 days of IL‐6‐mediated hyperinflammation in COVID‐19‐induced CSS in MP‐treated patients. Based on body weight PK simulations, a fixed‐dose tocilizumab of 400 mg should be considered to prevent overtreatment, future drug shortage and unnecessary drug expenditure.
- 28 January 2020
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 76 (5) , 739-740
Less is more: a cost benefit analysis of a changed posology for nivolumab
- 28 January 2020
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 76 (5) , 739-740
Less is more: a cost benefit analysis of a changed posology for nivolumab
- Open Access
Routine Assessment of Patient Index Data 3 (RAPID3) alone is insufficient to monitor disease activity in rheumatoid arthritis in clinical practice
Objective To test the longitudinal association between patient-reported outcome, Routine Assessment of Patient Index Data 3 (RAPID3) and the Disease Activity Score in 28 joints that includes the erythrocyte sedimentation rate (DAS28-ESR) in routine-care patients with rheumatoid arthritis (RA). Methods Patients with RA treated with disease-modifying antirheumatic drugs were included in this prospective observational cohort. The longitudinal association between RAPID3 (0–10) and DAS28-ESR and its individual components (swollen joint count (SJC), erythrocyte sedimentation rate (ESR) (mm/hour), tender joint count (TJC) and patient global assessment (PGA)) was tested using generalised estimating equations in patients with more than two consecutive visits with data on RAPID3 and DAS28-ESR. Interactions between RAPID3 and gender, pain, PGA and age at baseline were tested, and if significant (pResults In total, 330 patients were included (mean follow-up 10.7 (SD 9.7) months, female gender 67.9%). The longitudinal association between RAPID3 and DAS28-ESR was weak (β=0.29 (95% CI 0.24 to 0.35), n=207), meaning that one unit increase in RAPID3 corresponded to a 0.29 unit increase in Disease Activity Score in 28 joints (DAS28). RAPID3 was most strongly associated with subjective (TJC: β=0.89 (95% CI 0.61 to 1.17); PGA: β=0.94 (95% CI 0.84 to 1.04)) and not with objective components of DAS28 (SJC: β=0.29 (95% CI 0.17 to 0.41), n=172). The association between RAPID3 and ESR was poor but modified by gender, being only significant in men (β=0.37 (95% CI 0.08 to 0.67)). Conclusions These data suggest that RAPID3 does not sufficiently capture changes in objective inflammatory signs. Monitoring by RAPID3 alone is therefore insufficient to follow disease activity in patients wth RA in clinical practice.
Open AccessRoutine Assessment of Patient Index Data 3 (RAPID3) alone is insufficient to monitor disease activity in rheumatoid arthritis in clinical practice
Objective To test the longitudinal association between patient-reported outcome, Routine Assessment of Patient Index Data 3 (RAPID3) and the Disease Activity Score in 28 joints that includes the erythrocyte sedimentation rate (DAS28-ESR) in routine-care patients with rheumatoid arthritis (RA). Methods Patients with RA treated with disease-modifying antirheumatic drugs were included in this prospective observational cohort. The longitudinal association between RAPID3 (0–10) and DAS28-ESR and its individual components (swollen joint count (SJC), erythrocyte sedimentation rate (ESR) (mm/hour), tender joint count (TJC) and patient global assessment (PGA)) was tested using generalised estimating equations in patients with more than two consecutive visits with data on RAPID3 and DAS28-ESR. Interactions between RAPID3 and gender, pain, PGA and age at baseline were tested, and if significant (pResults In total, 330 patients were included (mean follow-up 10.7 (SD 9.7) months, female gender 67.9%). The longitudinal association between RAPID3 and DAS28-ESR was weak (β=0.29 (95% CI 0.24 to 0.35), n=207), meaning that one unit increase in RAPID3 corresponded to a 0.29 unit increase in Disease Activity Score in 28 joints (DAS28). RAPID3 was most strongly associated with subjective (TJC: β=0.89 (95% CI 0.61 to 1.17); PGA: β=0.94 (95% CI 0.84 to 1.04)) and not with objective components of DAS28 (SJC: β=0.29 (95% CI 0.17 to 0.41), n=172). The association between RAPID3 and ESR was poor but modified by gender, being only significant in men (β=0.37 (95% CI 0.08 to 0.67)). Conclusions These data suggest that RAPID3 does not sufficiently capture changes in objective inflammatory signs. Monitoring by RAPID3 alone is therefore insufficient to follow disease activity in patients wth RA in clinical practice.
- Open Access
Cotreatment with methotrexate in routine care patients with rheumatoid arthritis receiving biological treatment yields better outcomes over time
Objectives We aimed to evaluate the effects of methotrexate (MTX) comedication added to biological disease-modifying antirheumatic drugs (bDMARD) on disease activity measures in patients with rheumatoid arthritis (RA) in routine care. Methods Patients with RA on treatment with either bDMARDs or conventional synthetic DMARDs were included in this prospective cohort study. The effect of (time-varying) combination therapy with bDMARD and MTX compared with bDMARD monotherapy was tested in longitudinal generalised estimating equation models using as outcomes: (1) the likelihood to be in remission according to the 28-joint Disease Activity Score (DAS28) erythrocyte sedimentation rate (ESR) (Results In total, 330 patients were included (mean (SD) follow-up; 10.7 (9.7) months). Compared with bDMARD monotherapy, MTX combination therapy was significantly associated with a 55% higher likelihood to be in DAS28 remission, but not RAPID3 remission, over time. Combination therapy resulted in slightly, but statistically significant, lower levels of DAS28-ESR over time (β=−0.42 (95% CI −0.67 to − 0.17)), but not RAPID3 (β=−0.58 (95% CI −0.65 to 0.49)). The effect on DAS28-ESR was entirely explained by lower swollen joint counts and was persistent after correction for confounders. Conclusion These results give support to the policy that MTX should be continued in routine care patients with RA on biological therapy since this leads to better objective but not subjective clinical outcomes
Open AccessCotreatment with methotrexate in routine care patients with rheumatoid arthritis receiving biological treatment yields better outcomes over time
Objectives We aimed to evaluate the effects of methotrexate (MTX) comedication added to biological disease-modifying antirheumatic drugs (bDMARD) on disease activity measures in patients with rheumatoid arthritis (RA) in routine care. Methods Patients with RA on treatment with either bDMARDs or conventional synthetic DMARDs were included in this prospective cohort study. The effect of (time-varying) combination therapy with bDMARD and MTX compared with bDMARD monotherapy was tested in longitudinal generalised estimating equation models using as outcomes: (1) the likelihood to be in remission according to the 28-joint Disease Activity Score (DAS28) erythrocyte sedimentation rate (ESR) (Results In total, 330 patients were included (mean (SD) follow-up; 10.7 (9.7) months). Compared with bDMARD monotherapy, MTX combination therapy was significantly associated with a 55% higher likelihood to be in DAS28 remission, but not RAPID3 remission, over time. Combination therapy resulted in slightly, but statistically significant, lower levels of DAS28-ESR over time (β=−0.42 (95% CI −0.67 to − 0.17)), but not RAPID3 (β=−0.58 (95% CI −0.65 to 0.49)). The effect on DAS28-ESR was entirely explained by lower swollen joint counts and was persistent after correction for confounders. Conclusion These results give support to the policy that MTX should be continued in routine care patients with RA on biological therapy since this leads to better objective but not subjective clinical outcomes
- 31 May 2018
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 74 (10) , 1363
Non-specific treatment effects and the patient perception of costly drug therapy
- 31 May 2018
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 74 (10) , 1363
Non-specific treatment effects and the patient perception of costly drug therapy
- Open Access
- 24 January 2018
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 74 (5) , 655-661
The nocebo effect challenges the non-medical infliximab switch in practice
Background In clinical practice, non-medical switching of biological medication may provoke nocebo effects due to unexplained deterioration of therapeutic benefits. Indication extrapolation, idiosyncratic reactions, and interchangeability remain challenged in clinical practice after biosimilar approval by the European Medicines Agency. The principle of “first do no harm” may be challenged in a patient when switching from originator to biosimilar biological. Aim To describe the 1-year results of a pragmatic study on infliximab biosimilar implementation in immune-mediated inflammatory disease patients on the basis of shared decision-making under effectiveness and safety monitoring. Methods Inflammatory bowel disease and rheumatology patients on infliximab originator were converted to infliximab biosimilar after providing informed consent. Nocebo response patients were monitored after switch back to originator. Linear mixed models were used to analyze continuous endpoints on effectiveness and laboratory outcomes to determine significance (P ≤ 0.05) of change over time after switching. Results After inviting 146 patients, a group of 125 patients enrolled in the project over time, respectively, 73 Crohn’s disease, 28 ulcerative colitis, nine rheumatoid arthritis, ten psoriatic arthritis, and five ankylosing spondylitis patients. No statistically significant changes in effectiveness and safety were observed in any of the indications after a median of 4 infusions in 9 months of study. An overall nocebo response of 12.8% was found among the patients during a minimal observation period of 6 months after the transition to biosimilar infliximab. The overall nocebo response rate did not differ between the studied indications. Conclusions In inflammatory bowel disease and rheumatological patients, similar effectiveness and safety were demonstrated on the transition into infliximab biosimilar. In our series, patient empowerment and registration of treatment outcomes delineated biosimilar transition, an approach that hypothetically could reduce nocebo response rates which are relevant to account for regarding biosimilar implementation.
- 24 January 2018
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 74 (5) , 655-661
Open AccessThe nocebo effect challenges the non-medical infliximab switch in practice
Background In clinical practice, non-medical switching of biological medication may provoke nocebo effects due to unexplained deterioration of therapeutic benefits. Indication extrapolation, idiosyncratic reactions, and interchangeability remain challenged in clinical practice after biosimilar approval by the European Medicines Agency. The principle of “first do no harm” may be challenged in a patient when switching from originator to biosimilar biological. Aim To describe the 1-year results of a pragmatic study on infliximab biosimilar implementation in immune-mediated inflammatory disease patients on the basis of shared decision-making under effectiveness and safety monitoring. Methods Inflammatory bowel disease and rheumatology patients on infliximab originator were converted to infliximab biosimilar after providing informed consent. Nocebo response patients were monitored after switch back to originator. Linear mixed models were used to analyze continuous endpoints on effectiveness and laboratory outcomes to determine significance (P ≤ 0.05) of change over time after switching. Results After inviting 146 patients, a group of 125 patients enrolled in the project over time, respectively, 73 Crohn’s disease, 28 ulcerative colitis, nine rheumatoid arthritis, ten psoriatic arthritis, and five ankylosing spondylitis patients. No statistically significant changes in effectiveness and safety were observed in any of the indications after a median of 4 infusions in 9 months of study. An overall nocebo response of 12.8% was found among the patients during a minimal observation period of 6 months after the transition to biosimilar infliximab. The overall nocebo response rate did not differ between the studied indications. Conclusions In inflammatory bowel disease and rheumatological patients, similar effectiveness and safety were demonstrated on the transition into infliximab biosimilar. In our series, patient empowerment and registration of treatment outcomes delineated biosimilar transition, an approach that hypothetically could reduce nocebo response rates which are relevant to account for regarding biosimilar implementation.
- Open Access
- 28 August 2015
- Published by Springer Nature in SpringerPlus
- Vol. 4 (1) , 1-6
Evaluating patient reported outcomes in routine practice of patients with rheumatoid arthritis treated with biological disease modifying anti rheumatic drugs (b-DMARDs)
In this study the concordance between the Routine Assessment of Patient Index Data 3 (RAPID3) and the Disease Activity Score 28-joint count (DAS28) was investigated in a clinical routine outpatient setting. A sample of 150 adult patients with stable RA treated with biological DMARDs (bDMARDs) was asked to complete the RAPID3 (digital or on paper) just before their outpatient routine visit during which DAS28 assessment took place. The RAPID3 correlation with and the agreement in four DAS28 categories was studied using Spearman’s rank order and Cohen’s observed kappa statistics respectively. The positive (PPV) and negative (NPV) predictive values were calculated to test whether RAPID3 could make distinction in active disease (DAS28 >3.2) or not. A moderate correlation (ρ 0.576) and a poor kappa value of 0.13 were found in the whole study population. Patients reported a higher disease severity than was measured by DAS28. The PPV of RAPID3 for active disease by DAS28 was 0.59 (95 % CI 0.50–0.68) and the NPV was 0.91 (95 % CI 0.75–0.98) with a sensitivity and specificity of 96 and 40 % respectively. While RAPID3 correlates to some extent with DAS28 at the group level, agreement between RAPID3 and DAS28 at the individual patient level is to poor to rely on RAPID3 results in monitoring patients with RA. RAPID3 tends to over-report disease activity as assessed by DAS28.
- 28 August 2015
- Published by Springer Nature in SpringerPlus
- Vol. 4 (1) , 1-6
Open AccessEvaluating patient reported outcomes in routine practice of patients with rheumatoid arthritis treated with biological disease modifying anti rheumatic drugs (b-DMARDs)
In this study the concordance between the Routine Assessment of Patient Index Data 3 (RAPID3) and the Disease Activity Score 28-joint count (DAS28) was investigated in a clinical routine outpatient setting. A sample of 150 adult patients with stable RA treated with biological DMARDs (bDMARDs) was asked to complete the RAPID3 (digital or on paper) just before their outpatient routine visit during which DAS28 assessment took place. The RAPID3 correlation with and the agreement in four DAS28 categories was studied using Spearman’s rank order and Cohen’s observed kappa statistics respectively. The positive (PPV) and negative (NPV) predictive values were calculated to test whether RAPID3 could make distinction in active disease (DAS28 >3.2) or not. A moderate correlation (ρ 0.576) and a poor kappa value of 0.13 were found in the whole study population. Patients reported a higher disease severity than was measured by DAS28. The PPV of RAPID3 for active disease by DAS28 was 0.59 (95 % CI 0.50–0.68) and the NPV was 0.91 (95 % CI 0.75–0.98) with a sensitivity and specificity of 96 and 40 % respectively. While RAPID3 correlates to some extent with DAS28 at the group level, agreement between RAPID3 and DAS28 at the individual patient level is to poor to rely on RAPID3 results in monitoring patients with RA. RAPID3 tends to over-report disease activity as assessed by DAS28.